Use of bilirubin as a marker of adherence to atazanavir-based antiretroviral therapy

Kyle Petersen; Mark S. Riddle; Lindsay E. Jones; Kari J. Furtek; Anne R. Christensen; Sybil A. Tasker; Braden R. Hale

doi:10.1097/01.aids.0000186826.60983.85

Use of bilirubin as a marker of adherence to atazanavir-based antiretroviral therapy

Kyle Petersen^*, Mark S. Riddle, Lindsay E. Jones, Kari J. Furtek, Anne R. Christensen, Sybil A. Tasker, Braden R. Hale

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Abstract

We retrospectively reviewed 134 patients to evaluate atazanavir-related bilirubin elevation as an adherence marker. Using a 2 log reduction or undetectable viral load as a marker for suppression, the median bilirubin increase at first follow-up was 1.3 (0.7-2.2), versus 0.2 (-0.05-0.65) for those not suppressed. An increase in bilirubin of more than 0.4 mg/dl correctly classified 81% of patients as having successful treatment response (sensitivity 87%, specificity 63%), suggesting that bilirubin is a good adherence marker.

Original language	English
Pages (from-to)	1700-1702
Number of pages	3
Journal	AIDS
Volume	19
Issue number	15
DOIs	https://doi.org/10.1097/01.aids.0000186826.60983.85
State	Published - 14 Oct 2005

Access to Document

10.1097/01.aids.0000186826.60983.85

Cite this

@article{13b205eca7ad446a90568ea2a2b7fd95,

title = "Use of bilirubin as a marker of adherence to atazanavir-based antiretroviral therapy",

abstract = "We retrospectively reviewed 134 patients to evaluate atazanavir-related bilirubin elevation as an adherence marker. Using a 2 log reduction or undetectable viral load as a marker for suppression, the median bilirubin increase at first follow-up was 1.3 (0.7-2.2), versus 0.2 (-0.05-0.65) for those not suppressed. An increase in bilirubin of more than 0.4 mg/dl correctly classified 81% of patients as having successful treatment response (sensitivity 87%, specificity 63%), suggesting that bilirubin is a good adherence marker.",

author = "Kyle Petersen and Riddle, {Mark S.} and Jones, {Lindsay E.} and Furtek, {Kari J.} and Christensen, {Anne R.} and Tasker, {Sybil A.} and Hale, {Braden R.}",

year = "2005",

month = oct,

day = "14",

doi = "10.1097/01.aids.0000186826.60983.85",

language = "English",

volume = "19",

pages = "1700--1702",

journal = "AIDS",

issn = "0269-9370",

publisher = "Lippincott Williams and Wilkins",

number = "15",

}

TY - JOUR

T1 - Use of bilirubin as a marker of adherence to atazanavir-based antiretroviral therapy

AU - Petersen, Kyle

AU - Riddle, Mark S.

AU - Jones, Lindsay E.

AU - Furtek, Kari J.

AU - Christensen, Anne R.

AU - Tasker, Sybil A.

AU - Hale, Braden R.

PY - 2005/10/14

Y1 - 2005/10/14

N2 - We retrospectively reviewed 134 patients to evaluate atazanavir-related bilirubin elevation as an adherence marker. Using a 2 log reduction or undetectable viral load as a marker for suppression, the median bilirubin increase at first follow-up was 1.3 (0.7-2.2), versus 0.2 (-0.05-0.65) for those not suppressed. An increase in bilirubin of more than 0.4 mg/dl correctly classified 81% of patients as having successful treatment response (sensitivity 87%, specificity 63%), suggesting that bilirubin is a good adherence marker.

AB - We retrospectively reviewed 134 patients to evaluate atazanavir-related bilirubin elevation as an adherence marker. Using a 2 log reduction or undetectable viral load as a marker for suppression, the median bilirubin increase at first follow-up was 1.3 (0.7-2.2), versus 0.2 (-0.05-0.65) for those not suppressed. An increase in bilirubin of more than 0.4 mg/dl correctly classified 81% of patients as having successful treatment response (sensitivity 87%, specificity 63%), suggesting that bilirubin is a good adherence marker.

UR - http://www.scopus.com/inward/record.url?scp=27144518127&partnerID=8YFLogxK

U2 - 10.1097/01.aids.0000186826.60983.85

DO - 10.1097/01.aids.0000186826.60983.85

M3 - Article

C2 - 16184044

AN - SCOPUS:27144518127

SN - 0269-9370

VL - 19

SP - 1700

EP - 1702

JO - AIDS

JF - AIDS

IS - 15

ER -

Use of bilirubin as a marker of adherence to atazanavir-based antiretroviral therapy

Abstract

Access to Document

Fingerprint

Cite this